Bluebird Bio's gene therapy has defeated one genetic disease – many more await
Bluebird Bio's gene therapy has shown groundbreaking results against the genetic disease beta thalassemia, and CSO Philip Gregory expects that the company can do the same for many more diseases.
BY KEVIN GRØNNEMANN, TRANSLATED BY KEVIN GRØNNEMANN
Philip Gregory, chief scientific officer with the American biotech company Bluebird Bio, is a man with great ambitions and the means to fulfill them.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
